Article Text

Download PDFPDF
Serum LDH and exercise capacity in COPD
  1. M A Spruit1,
  2. H J Pennings2,
  3. J D Does2,
  4. G M Möller4,
  5. P P Janssen1,
  6. E F M Wouters3,4
  1. 1
    Department of Research, Development and Education, Centre for Integrated Rehabilitation of Organ failure (CIRO), Horn, The Netherlands
  2. 2
    Department of Respiratory Medicine, Centre for Integrated Rehabilitation of Organ failure (CIRO), Horn, The Netherlands
  3. 3
    Centre for Integrated Rehabilitation of Organ failure (CIRO), Horn, The Netherlands
  4. 4
    Department of Respiratory Medicine, University Hospital Maastricht, Maastricht, The Netherlands
  1. Dr M A Spruit, Department of Research, Development and Education, Centre for Integrated Rehabilitation of Organ failure (CIRO), 6085 NM, Horn, The Netherlands; martijnspruit{at}proteion.nl

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Lactate dehydrogenase (LDH) is the enzyme that catalyses the final step in the glycolytic metabolism, regenerating NAD+ from reduced NADH, by conversion of pyruvate to lactate.1 Recently, increased muscle LDH activity has been found in elderly male patients with chronic obstructive pulmonary disease (COPD) who were susceptible to contractile fatigue of the quadriceps femoris muscle following constant work rate cycle exercise performed at 80% of the predetermined peak work rate.2 Moreover, increased resting serum LDH activity has been found in patients with COPD compared with healthy smoking and non-smoking peers.3 To date, it remains unknown whether and to what extent increased resting serum LDH activity may be linked to a reduced …

View Full Text

Footnotes

  • Funding: For the present study, MAS was awarded the ERS COPD Travel Grant for Best Posters 2006, supported by Boehringer Ingelheim.

  • Competing interests: None.